ArticleThe Journal of antibiotics2025
PPtase-activated production of borrelidin from extremophilic actinobacteria against multidrug-resistant cotton pathogen Verticillium dahliae.
Article in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
As the most devastating disease in cotton crops, Verticillium wilt caused by Verticillium dahliae led to fiber quality reduction and extensive yield loss. In recent years, Verticillium wilt has been increasingly serious in Xinjiang, China, the world's largest cotton production area. In this study, 52 actinobacterial strains were selected for the discovery of NPs with anti-V. dahliae activity, from our strain collection isolated from three types of extreme habitats (high salinity, high temperature or plant endophytes) in Xinjiang. In the culture broth extracts of phosphopantetheinyl transferase (PPtase)-activated actinobacterial strains, four showed good anti-V. dahliae activities. By isolation, purification and spectral analysis of the antifungal metabolite, its structure was elucidated as borrelidin from Streptomyces rochei TRM46813. This is the first report that borrelidin shows anti-V. dahliae activity. Notably, borrelidin could effectively inhibit different commercial fungicides-resistant V. dahliae pathogens with MICs of 0.125 to 2 μg/mL. The growth-inhibitory effect was antagonized by L-threonine in a dose-dependent manner, suggesting that threonyl-tRNA synthetase (ThrRS) may be the target of borrelidin in V. dahliae. Interestingly, although borrelidin was previously reported to bind to ThrRS and thus inhibit protein translation in Gram-positive pathogens, our mode-of-action analysis indicates that borrelidin led to the accumulation of cell wall precursor, which may be due to the inhibited effects on protein translation. Our findings suggest that borrelidin is a promising candidate for the development of novel antifungal agents to overcome the growing problem of Verticillium wilt.
Indexed as
Identifiers
39910347What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.